Vera Clinic | June 2026 | Next review: September 2026
Last updated: June 2026
Exosome Therapy at a Glance: Key Statistics for 2025 to 2026
- Exosome therapy is a non-surgical regenerative treatment that uses stem-cell-derived extracellular vesicles, small membrane particles generally 40 to 160 nm in diameter, applied to support the follicular environment rather than to replace hair transplant surgery (Schaffer et al., 2025; Vera Clinic Academy Database, 2026).
- A 2025 clinical review of exosome use in human subjects found 9 studies relevant to alopecia, covering 125 patients treated for hair loss, with rare local side effects, and concluded that larger controlled trials are needed to prove efficacy (Queen and Avram, Dermatologic Surgery, 2025).
- The global exosomes market was valued at $177.3 million in 2024 and is projected to reach $794.2 million by 2030, growing at a CAGR of 28.7%, driven mainly by research, isolation, and diagnostic applications rather than hair restoration (Grand View Research, 2025).
- Mesenchymal stem cell-derived exosomes are the most studied source in hair-related research, and North America held 56.6% of global exosome revenue in 2024 (Grand View Research, 2025).
- A standalone, non-surgical exosome session is priced between €1,500 and €2,500 in Turkey, compared with €3,500 to €4,200 in the UK and €4,800 to €5,500 in the United States (Vera Clinic Academy Database, 2026).
- At Vera Clinic, exosome therapy is delivered as a post-transplant regenerative layer within the Exosome Therapy package priced from €5,990, which combines Sapphire FUE or DHI surgery with exosome application and supporting recovery protocols (Vera Clinic Academy Database, 2026).
- Reported graft survival for the Sapphire FUE or DHI procedures performed within these packages is 90 to 95% at 12 months, with top-tier cases reaching up to 98%, attributed to the surgical technique rather than to exosome therapy in isolation (Vera Clinic Academy Database, 2026).
Methodology and Data Provenance
This study presents statistics on exosome therapy as applied within hair restoration, including the Vera Clinic protocol in which exosome therapy is used as a post-transplant regenerative layer. Because no large-scale, hair-transplant-specific clinical outcome dataset exists for exosome therapy, this study separates several distinct evidence tiers. First, Vera Clinic protocol parameters, package contents, and pricing are drawn from the clinic’s published exosome documentation and its internal clinical database. Second, the mechanism and clinical evidence are drawn from peer-reviewed exosome and regenerative-medicine literature, where the human clinical evidence base is early and limited and a large share of the mechanistic evidence is preclinical, based on cell and animal models. Third, regulatory status is drawn from the U.S. Food and Drug Administration. Fourth, market sizing is drawn from a named research firm and describes the broad exosomes sector rather than a hair-restoration-specific market. Where graft survival figures appear, they describe the Sapphire FUE or DHI surgical benchmarks and are attributed to the surgical technique, not to exosome therapy in isolation.
Data Sources
The table below lists the primary sources used in this study, with the metric categories each one supports and the period it covers.
| Source | Description | Coverage Period |
|---|---|---|
| Vera Clinic Academy Database, 2026 | Vera Clinic internal clinical database and published exosome documentation; protocol parameters, package and pricing data, operational metrics, and procedural outcomes | 2025 to 2026 |
| Queen and Avram, Dermatologic Surgery, 2025 | Clinical review of exosome use in human subjects, focused on safety and efficacy in androgenetic and non-scarring alopecia | 2025 |
| Al Ameer et al., Clinical, Cosmetic and Investigational Dermatology, 2025 | Systematic review of clinical evidence for exosomes in hair regeneration across alopecia types and exosome sources | 2025 |
| Schaffer et al., Cureus, 2025 | Scoping review of exosome delivery mechanisms and size range in hair loss | 2018 to 2023 |
| Oh et al., Stem Cell Research & Therapy, 2024 | Preclinical study of mesenchymal stem cell-derived extracellular vesicles in androgenetic alopecia, conducted in a mouse model | 2024 |
| Park et al., J Cosmet Dermatol, 2022 | Retrospective analysis of 39 AGA patients treated with adipose-derived stem cell exosomes | 2022 |
| Gupta et al., J Cosmet Dermatol, 2023 | Systematic review of exosome treatment in hair restoration; preliminary evidence and safety | 2023 |
| U.S. Food and Drug Administration, 2019 | Public safety notification and regulatory status of stem cell and exosome products | 2019 |
| Grand View Research, 2025 | Global exosomes market sizing, segmentation, and forecast | 2024 to 2033 |
The Vera Clinic Academy Database (2026) contains clinical data collected between January and December 2025, compiled and reviewed for publication in June 2026.
Known Limitations
Exosome therapy in hair restoration is an emerging, investigational regenerative therapy, and the human clinical evidence base is early and limited, with much of the supporting mechanistic evidence drawn from preclinical cell and animal models; the figures here describe a mechanism and an early evidence base, not measured exosome outcomes in Vera Clinic patients. Vera Clinic data is self-reported and not independently verified, with a conflict of interest disclosure at the opening of the Vera Clinic in Numbers section. Market sizing describes the broad exosomes sector and is presented as context only, not a hair-restoration-specific market. Graft survival figures are reported within the Sapphire FUE and DHI benchmarks and attributed to the surgical technique, not to exosome therapy in isolation.
Definitions
| Term | Definition |
|---|---|
| FUE (Follicular Unit Extraction) | A hair transplant method in which individual follicular units are extracted from the donor area using a micro-punch and implanted into recipient channels created in the scalp |
| DHI (Direct Hair Implantation) | A variation of FUE in which extracted grafts are placed directly into the scalp using a Choi implanter pen, without prior channel creation in the recipient area |
| Sapphire FUE | A variation of FUE in which recipient channels are created using a blade made from medical-grade corundum (Al₂O₃), associated with higher channel precision and reduced tissue trauma compared to steel-blade FUE |
| Exosome / Extracellular Vesicle | A small, membrane-bound particle generally 40 to 160 nm in diameter that cells release to carry proteins, lipids, and RNA between cells; it transfers biological signals but does not divide or contain a living cell |
| Mesenchymal Stem Cell (MSC) | A type of adult stem cell, commonly sourced from adipose tissue, bone marrow, or umbilical cord, widely studied as a source of exosomes used in regenerative research |
| Androgenetic Alopecia (AGA) | The most common form of hereditary hair loss, driven by androgen sensitivity of the hair follicle, presenting as patterned thinning in men and women |
| Dermal Papilla Cell | A specialized cell population at the base of the hair follicle that regulates the hair growth cycle and is a primary target of exosome signaling in preclinical studies |
| Adjunctive / Regenerative Therapy | A treatment used alongside a primary procedure to support its outcome, rather than as a stand-alone treatment in its own right |
| Graft / Follicular Unit | A naturally occurring group of 1 to 4 hairs sharing a common dermal papilla; the standard unit of measurement for hair transplant procedures |
| Graft Survival Rate | The percentage of transplanted follicular units that produce viable hair growth at a defined follow-up point, most commonly 12 months post-procedure |
| Patient Satisfaction | A self-reported measure of how closely an outcome meets patient expectations, distinct from the clinically measured graft survival rate |
| Preclinical vs. Clinical Evidence | Preclinical evidence comes from laboratory cell or animal studies, while clinical evidence comes from studies in human patients; exosome hair research today rests largely on preclinical work |
| Investigational / Off-Label Use | Use of a product or therapy that has not received regulatory approval for the specific application in which it is being administered |
Exosome Therapy: Definition and Scientific Background
Exosome therapy is a non-surgical regenerative treatment that uses exosomes, a class of small extracellular vesicles generally 40 to 160 nm in diameter, which cells release to carry proteins, lipids, microRNAs, and growth factors between cells (Schaffer et al., 2025). Unlike stem cell treatments, exosomes contain no living cells and cannot divide; they transfer biological signals only (Queen and Avram, 2025). In hair restoration research, exosomes are most commonly derived from mesenchymal stem cells, including those sourced from adipose tissue, bone marrow, and umbilical cord (Al Ameer et al., 2025).
In preclinical cell and animal studies, exosomes have been reported to act on dermal papilla cells, the cell population that regulates the hair growth cycle, and to influence signaling associated with the transition from the resting telogen phase to the active anagen phase (Oh et al., 2024). These models describe increased dermal papilla cell activity and elevated growth factors such as vascular endothelial growth factor and insulin-like growth factor 1 (Oh et al., 2024). The mechanisms are documented in laboratory and animal models and have not been confirmed as measured outcomes in human hair transplant patients (Queen and Avram, 2025).
At Vera Clinic, exosome therapy is applied as a post-transplant regenerative layer rather than as a stand-alone hair growth treatment, positioned to support the recovery environment after Sapphire FUE or DHI surgery (Vera Clinic Academy Database, 2026). The clinic does not present its exosome hair loss treatment as a method that creates new follicles in fully bald areas or reverses genetic hair loss on its own (Vera Clinic Academy Database, 2026).
Key statistic: Exosomes are small extracellular vesicles generally 40 to 160 nm in diameter that transfer proteins, lipids, and RNA between cells without containing any living cell, which is the basis for their use as a regenerative signaling layer rather than a cell transplant (Schaffer et al., 2025).
Global Exosome and Regenerative Medicine Market
The global exosomes market was valued at $177.3 million in 2024 and is projected to reach $794.2 million by 2030, growing at a compound annual growth rate of 28.7% over the period (Grand View Research, 2025). This market is led by research, isolation, and diagnostic applications, with kits and reagents the largest product segment and cancer the largest application area, rather than by hair restoration (Grand View Research, 2025).
North America held 56.6% of global exosome revenue in 2024, the largest regional share (Grand View Research, 2025). A separate forecast for the narrower exosome-based therapeutics market valued it at $56.28 million in 2025, with a projection to reach $220.20 million by 2033 at a compound annual growth rate of 18.66%, and identified mesenchymal stem cell-derived exosomes as the largest source segment (Grand View Research, 2025).
These figures describe the broad exosomes sector and its research and therapeutic-development pipeline. They establish the scale and growth of exosome science as context for its emerging use in hair transplantation procedures, where adoption is early and no hair-restoration-specific market sizing is established (Al Ameer et al., 2025).
Key statistic: The global exosomes market is projected to grow from $177.3 million in 2024 to $794.2 million by 2030 at a compound annual growth rate of 28.7%, led by research and diagnostic applications rather than hair restoration (Grand View Research, 2025).
Clinical Evidence on Exosomes in Hair Transplantation
The clinical evidence for exosome therapy in hair loss is early and limited. A 2025 systematic review of clinical studies identified 11 studies, comprising 2 randomized controlled trials, 3 retrospective studies, 3 prospective single-arm studies, 1 case series, and 2 case reports, and concluded that the safety and efficacy of exosome therapy for alopecia remain to be determined (Al Ameer et al., 2025).
A separate 2025 clinical review of exosome use in human subjects found 9 studies relevant to alopecia, covering 125 patients treated for hair loss (Queen and Avram, 2025). Local side effects were rare in these studies, although at least 10 serious adverse events have been reported across the broader field of dermatology, and the review called for larger, well-designed trials with extended follow-up to prove efficacy (Queen and Avram, 2025).
A retrospective analysis of 39 androgenetic alopecia patients treated with adipose-derived stem cell exosomes reported an increase in mean hair density from 121.7 to 146.6 hairs per cm² and in mean hair thickness from 52.6 to 61.4 micrometres, with no significant adverse reactions, although the study was retrospective and single-centre (Park et al., 2022). A separate 2023 systematic review identified 16 studies, 15 of them preclinical and 1 clinical, and reported no significant adverse reactions from exosome treatment to date (Gupta et al., 2023).
Much of the supporting evidence is preclinical. In a 2024 study using a testosterone-induced androgenetic alopecia mouse model, mesenchymal stem cell-derived extracellular vesicles were reported to support hair regrowth and follicle cycling (Oh et al., 2024). These are laboratory and animal findings that describe a biological mechanism rather than measured outcomes in human hair transplant patients (Queen and Avram, 2025).
Within Vera Clinic packages, exosome therapy is applied after Sapphire FUE or DHI surgery to support the early recovery environment. Reported graft survival of 90 to 95% at 12 months, with top-tier cases reaching up to 98%, is attributed to the surgical technique and not to exosome therapy in isolation (Vera Clinic Academy Database, 2026).
Key statistic: A 2025 systematic review identified only 11 clinical studies of exosomes for hair loss, including 2 randomized controlled trials, and concluded that the safety and efficacy of exosome therapy for alopecia remain to be determined (Al Ameer et al., 2025).
Exosomes vs PRP vs Stem Cell Therapy
The table below compares three regenerative approaches used alongside hair restoration, based on their biological basis, evidence maturity, and regulatory status. All three are used as supportive therapies rather than as replacements for hair transplant surgery.
| Feature | PRP | Stem Cell-Derived Exosomes | Stem Cell Therapy |
|---|---|---|---|
| Biological basis | Concentrated platelets and growth factors from the patient’s own blood | Cell-free extracellular vesicles that carry signaling proteins, lipids, and RNA | Living stem cells, most commonly adipose-derived |
| Source material | Autologous, drawn from the patient | Donor stem cell cultures, most commonly mesenchymal stem cells | Autologous or donor stem cells |
| Contains living cells | No | No | Yes |
| Human evidence in hair loss | The most established of the three, with multiple clinical trials | Early and limited, based on a small number of clinical studies | Limited, with regenerative studies ongoing |
| FDA approval for hair loss | Not an approved drug; used as an in-clinic procedure | Investigational; not yet an approved therapy | No approval for hair loss; stem cell approvals cover certain blood and immune disorders |
| Role in hair restoration | Supportive therapy alongside surgery | Supportive, post-transplant regenerative layer | Supportive regenerative therapy |
Of the three, platelet-rich plasma has the most established clinical track record in hair loss, while exosome therapy is the newest and rests on early, limited human evidence; all three remain investigational for hair loss, and all three are used as supportive therapies alongside surgery rather than as replacements for it (Al Ameer et al., 2025; Queen and Avram, 2025; U.S. Food and Drug Administration, 2019).
Key statistic: Among regenerative options used alongside hair restoration, exosome therapy has the least mature human evidence base of the three compared here, resting on a small number of clinical studies (Al Ameer et al., 2025).
Integration with Sapphire FUE and DHI Procedures
At Vera Clinic, exosome therapy is integrated as a post-transplant regenerative layer within the surgical workflow rather than offered as a stand-alone session, and it is paired with the clinic’s recovery protocols after Sapphire FUE or DHI surgery (Vera Clinic Academy Database, 2026).
- Sapphire FUE pairing: Exosome therapy is applied after Sapphire FUE, in which sapphire blades create the recipient channels, to support the early healing environment of the grafted area (Vera Clinic Academy Database, 2026).
- DHI pairing: Exosome therapy is also paired with DHI, in which grafts are placed directly with an implanter pen, within the same post-transplant regenerative protocol (Vera Clinic Academy Database, 2026).
- OxyCure combination: Within enhanced-recovery packages, exosome therapy is combined with OxyCure hyperbaric oxygen therapy, which supports the post-surgical oxygen environment of the scalp (Vera Clinic Academy Database, 2026).
- Recovery supplement window: The regenerative protocol is supported by a 6 to 12 month recovery supplement plan included in the package (Vera Clinic Academy Database, 2026).
- Position in the workflow: Exosome therapy is applied as a supportive layer and does not replace the surgical procedure, the donor harvest, or graft placement (Vera Clinic Academy Database, 2026).
Key statistic: At Vera Clinic, exosome therapy is delivered only as a post-transplant regenerative layer paired with Sapphire FUE or DHI surgery and OxyCure recovery support, not as a stand-alone procedure (Vera Clinic Academy Database, 2026).
Exosome Therapy Cost Statistics
The cost of a standalone, non-surgical exosome session varies by country and clinic infrastructure. The table below compares the price of a single exosome session across Turkey, the UK, and the United States.
| Country | Average Cost per Session |
|---|---|
| Turkey | €1,500 to €2,500 |
| UK | €3,500 to €4,200 |
| USA | €4,800 to €5,500 |
A standalone exosome session in Turkey is priced below the UK and United States ranges, in line with the broader cost gap seen across hair restoration services delivered in Turkey (Vera Clinic Academy Database, 2026).
Key statistic: A standalone, non-surgical exosome session is priced between €1,500 and €2,500 in Turkey, compared with €3,500 to €4,200 in the UK and €4,800 to €5,500 in the United States (Vera Clinic Academy Database, 2026).
Vera Clinic Exosome Therapy in Numbers
The data in this section is Vera Clinic’s own self-reported operational and clinical data. It has not been independently third-party verified and should be read as the clinic’s internal record, distinct from the peer-reviewed and market data cited elsewhere in this study (Vera Clinic Academy Database, 2026).
At Vera Clinic, exosome therapy is offered within the Exosome Therapy package priced from €5,990, which combines Sapphire FUE or DHI surgery with a post-transplant exosome application, OxyCure therapy, PRP, laser therapy, a 6 to 12 month recovery supplement kit, premium accommodation, and VIP transfers (Vera Clinic Academy Database, 2026). The package sits at the clinic’s upper regenerative tier, alongside the stem cell package (Vera Clinic Academy Database, 2026).
Operational Metrics
| Metric | Data Point | Source |
|---|---|---|
| Cumulative procedures performed | More than 40,000 since 2013 | Vera Clinic Academy Database, 2026 |
| Exosome-inclusive package | Exosome Therapy package from €5,990 | Vera Clinic Academy Database, 2026 |
| Exosome application format | Post-transplant regenerative layer | Vera Clinic Academy Database, 2026 |
| Exosome application duration | 30 to 45 minutes | Vera Clinic Academy Database, 2026 |
| Recovery supplement plan | 6 to 12 months | Vera Clinic Academy Database, 2026 |
Clinical Outcomes
| Outcome Metric | Data Point | Source |
|---|---|---|
| Reported patient satisfaction rate | 98% | Vera Clinic Academy Database, 2026 |
| Reported graft survival (Sapphire FUE or DHI) | 90 to 95% at 12 months, with top-tier cases up to 98% | Vera Clinic Academy Database, 2026 |
| Revision or corrective procedure rate | Less than 2% | Vera Clinic Academy Database, 2026 |
The graft survival figures above are reported within the Sapphire FUE or DHI protocol benchmarks and are attributed to the surgical technique, consistent with the clinic’s position that exosome therapy supports the healing environment rather than driving density on its own (Vera Clinic Academy Database, 2026).
Accreditations
| Accreditation / Recognition | Detail | Source |
|---|---|---|
| ISO 9001:2015 certification | Active from 2020 | Vera Clinic Academy Database, 2026 |
| Turkish Ministry of Health licensing | Active; all requisite permits current | Vera Clinic Academy Database, 2026 |
| ISHRS membership | Surgeons hold active ISHRS membership | Vera Clinic Academy Database, 2026 |
Key statistic: Vera Clinic reports a patient satisfaction rate of 98% and graft survival of 90 to 95% at 12 months for the Sapphire FUE or DHI procedures performed within its exosome-inclusive packages, with these outcomes attributed to the surgical technique (Vera Clinic Academy Database, 2026).
Frequently Asked Questions: Exosome Therapy
Exosome therapy functions as a post-transplant regenerative layer, not a replacement for surgery. Applied after Sapphire FUE or DHI, it delivers cell-free signaling molecules including VEGF, IGF-1, and microRNAs to support the healing environment around transplanted grafts. It does not create new follicles and is classified as investigational for hair loss (Al Ameer et al., 2025; Vera Clinic Academy Database, 2026).
Of the two, PRP has the more established clinical track record in hair loss, with multiple published trials, while exosome therapy rests on a smaller number of early human studies. PRP delivers platelet-derived growth factors from the patient’s own blood; exosomes deliver cell-free RNA and protein signals from donor stem cell cultures (Al Ameer et al., 2025; Queen and Avram, 2025).
No. Exosome therapy is a supportive regenerative layer, not a replacement for surgery, and it does not create new follicles in fully bald areas. At Vera Clinic it is applied after Sapphire FUE or DHI to support the recovery environment rather than as a stand-alone restoration method (Vera Clinic Academy Database, 2026).
No. Exosomes are cell-free extracellular vesicles, not living stem cells; they carry signaling molecules such as proteins, lipids, and RNA but cannot divide or alter DNA. This is why exosome therapy is described as cell-free regenerative signaling rather than a stem cell transplant (Al Ameer et al., 2025; Queen and Avram, 2025).
In the limited clinical studies to date, local side effects from exosome treatment for hair loss have been rare. However, at least 10 serious adverse events have been reported across the broader field of dermatology, and the FDA has advised caution regarding unapproved exosome products, so larger trials are needed to confirm safety (Queen and Avram, 2025; U.S. Food and Drug Administration, 2019).
A standalone exosome session costs between €1,500 and €2,500 in Turkey, compared with €3,500 to €4,200 in the UK and €4,800 to €5,500 in the United States. At Vera Clinic, exosome therapy is offered within a combined package from €5,990, which includes Sapphire FUE or DHI surgery, OxyCure therapy, PRP, laser therapy, and VIP accommodation (Vera Clinic Academy Database, 2026).
Exosome therapy is offered at Vera Clinic in Istanbul, Turkey, within the Exosome Therapy package from €5,990, which combines Sapphire FUE or DHI surgery with a post-transplant exosome application and recovery support. Exosome therapy is applied as a regenerative layer (Vera Clinic Academy Database, 2026).
Sources and Citations
Medical Authorities
- U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. 2019. https://www.fda.gov/safety/medical-product-safety-information/public-safety-alert-due-marketing-unapproved-stem-cell-and-exosome-products. Accessed June 2026.
Clinical and Preclinical Studies
- Queen D, Avram MR. Exosomes for Treating Hair Loss: A Review of Clinical Studies. Dermatologic Surgery. 2025;51(4):409-415. PMID: 39447204. https://journals.lww.com/dermatologicsurgery/abstract/9900/exosomes_for_treating_hair_loss__a_review_of.1015.aspx. Accessed June 2026.
- Al Ameer MA, Alnajim AT, Al Ameer A, et al. Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources. Clinical, Cosmetic and Investigational Dermatology. 2025;18:2215-2227. https://pmc.ncbi.nlm.nih.gov/articles/PMC12433634/. Accessed June 2026.
- Schaffer S, Tehrani L, Koechle B, et al. A Scoping Review of Exosome Delivery Applications in Hair Loss. Cureus. 2025;17(3):e81152. doi:10.7759/cureus.81152. Accessed June 2026.
- Oh HG, Jung M, Jeong SY, et al. Improvement of androgenic alopecia by extracellular vesicles secreted from hyaluronic acid-stimulated induced mesenchymal stem cells. Stem Cell Research & Therapy. 2024;15:287. PMID: 39256806. https://stemcellres.biomedcentral.com/articles/10.1186/s13287-024-03906-x. Accessed June 2026.
- Park BS, Choi HI, Huh G, Kim WS. Effects of exosome from adipose-derived stem cell on hair loss: a retrospective analysis of 39 patients. J Cosmet Dermatol. 2022;21(5):2282-2284. doi:10.1111/jocd.14846. Accessed June 2026.
- Gupta AK, Wang T, Rapaport JA. Systematic review of exosome treatment in hair restoration: preliminary evidence, safety, and future directions. J Cosmet Dermatol. 2023;22(9):2424-2433. doi:10.1111/jocd.15869. Accessed June 2026.
Market Reports
- Grand View Research. Exosomes Market Size, Share & Trends Analysis Report. 2025. https://www.grandviewresearch.com/industry-analysis/exosomes-market. Accessed June 2026.
- Grand View Research. Exosome-based Therapeutics Market Report. 2025. https://www.grandviewresearch.com/industry-analysis/exosome-based-therapeutics-market-report. Accessed June 2026.
Clinical Database and Clinic Sources
- Vera Clinic. Exosome Hair Loss Treatment: Session, Cost, and Results. 2026. https://www.veraclinic.net/exosome-hair-loss-treatment/. Accessed June 2026.
- Vera Clinic. Hair Transplant Turkey Cost 2026. 2026. https://www.veraclinic.net/hair-transplant-turkey-cost/. Accessed June 2026.
- Vera Clinic Academy Database. Internal clinical database of procedural, operational, and outcome data. Istanbul, Turkey. 2026. Referenced throughout as (Vera Clinic Academy Database, 2026). Accessed June 2026.
Version Log
| Date | Version | Change Description | Reason |
|---|---|---|---|
| June 2026 | 1.0 | Initial publication | Comprehensive 2026 data compilation; first statistics study for exosome therapy in hair transplantation |
Next review: September 2026.